Insulet Corporation with ticker code (PODD) now have 20 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $264.00 and $185.00 with the average share target price sitting at $235.02. (at the time of writing). Given that the stocks previous close was at $182.19 this indicates there is a potential upside of 29.0%. It’s also worth noting that there is a 50 day moving average of $195.70 while the 200 day moving average is $184.74. The market cap for the company is 13.19B. The price for the stock stands currently at: $188.05 USD
The potential market cap would be $17,008,565,494 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 34.01, revenue per share of $26.78 and a 6.85% return on assets.
Insulet Corporation is primarily engaged in the development, manufacture and sale of its Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) that the user fills with insulin and wears directly on the body for up to three days at a time, which delivers personalized doses of insulin, and the Personal Diabetes Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta.
